


z is 1.

Conclusion

Applicants elected the species, Compound (V) and affirm their right to file one or more divisional applications with respect to any of the non-elected subject matter.

If a telephone interview would be of assistance in advancing prosecution of this application, Applicant's agent invites the Examiner to contact him at the number provided below.

Respectfully submitted,




Dated: October 22, 2001

Peter L. Dolan, Ph.D.
Agent for Applicants
Registration No. 46,307
(302)992-4528

Appendix 1
Marked-Up Version of Rewritten Claims

6. (Amended) The method of Claim 4 wherein the localization step comprises the step of localizing a compound of the formula (I) at the thrombus wherein Q is of the formula (II),



(II)

or a pharmaceutically acceptable salt or prodrug form thereof wherein:

R³¹ is a C₆-C₁₄ saturated, partially saturated, or aromatic carbocyclic ring system substituted with 0-4 R¹⁰ or R^{10a};

R³² is selected from:

- C(=O)-;
- C(=S)-
- S(=O)₂-;
- S(=O)-;
- P(=Z)(ZR¹³)-;

Z is S or O;

n'' and n' are independently 0-2;

R^1 and R^{22} are independently selected from the following groups:

hydrogen,

C1-C8 alkyl substituted with 0-2 R^{11} ;

C2-C8 alkenyl substituted with 0-2 R^{11} ;

C2-C8 alkynyl substituted with 0-2 R^{11} ;

C3-C10 cycloalkyl substituted with 0-2 R^{11} ;

aryl substituted with 0-2 R^{12} ;

a 5-10-membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O, said heterocyclic ring being substituted with 0-2 R^{12} ;

=O, F, Cl, Br, I, $-CF_3$, $-CN$, $-CO_2R^{13}$, $-C(=O)R^{13}$, $-C(=O)N(R^{13})_2$, $-CHO$, $-CH_2OR^{13}$, $-OC(=O)R^{13}$, $-OC(=O)OR^{13a}$, $-OR^{13}$, $-OC(=O)N(R^{13})_2$, $-NR^{13}C(=O)R^{13}$, $-NR^{14}C(=O)OR^{13a}$, $-NR^{13}C(=O)N(R^{13})_2$, $-NR^{14}SO_2N(R^{13})_2$, $-NR^{14}SO_2R^{13a}$, $-SO_3H$, $-SO_2R^{13a}$, $-SR^{13}$, $-S(=O)R^{13a}$, $-SO_2N(R^{13})_2$, $-N(R^{13})_2$, $-NHC(=NH)NHR^{13}$, $-C(=NH)NHR^{13}$, $=NOR^{13}$, NO_2 , $-C(=O)NHOR^{13}$, $-C(=O)NHN(R^{13})R^{13a}$, $-OCH_2CO_2H$, 2-(1-morpholino)ethoxy;

R^1 and R^{21} can alternatively join to form a 3-7 membered carbocyclic ring substituted with 0-2 R^{12} ;

when n' is 2, R^1 or R^{21} can alternatively be taken together with R^1 or R^{21} on an adjacent carbon atom to form a direct bond, thereby to form a double or triple bond between said carbon atoms;

R^{22} and R^{23} can alternatively join to form a 3-7 membered carbocyclic ring substituted with 0-2 R^{12} ;

when n'' is 2, R^{22} or R^{23} can alternatively be taken together with R^{22} or R^{23} on an adjacent carbon atom to form a direct bond, thereby to form a double or triple bond between the adjacent carbon atoms;

R^1 and R^2 , where R^{21} is H, can alternatively join to form a 5-8 membered carbocyclic ring substituted with 0-2 R^{12} ;

R^{11} is selected from one or more of the following:

=O, F, Cl, Br, I, $-CF_3$, $-CN$, $-CO_2R^{13}$, $-C(=O)R^{13}$, $-C(=O)N(R^{13})_2$, $-CHO$, $-CH_2OR^{13}$, $-OC(=O)R^{13}$, $-OC(=O)OR^{13a}$, $-OR^{13}$, $-OC(=O)N(R^{13})_2$, $-NR^{13}C(=O)R^{13}$, $-NR^{14}C(=O)OR^{13a}$, $-NR^{13}C(=O)N(R^{13})_2$, $-NR^{14}SO_2N(R^{13})_2$, $-NR^{14}SO_2R^{13a}$, $-SO_3H$, $-SO_2R^{13a}$, $-SR^{13}$, $-S(=O)R^{13a}$, $-SO_2N(R^{13})_2$, $-N(R^{13})_2$, $-NHC(=NH)NHR^{13}$, $-C(=NH)NHR^{13}$, $=NOR^{13}$, NO_2 , $-C(=O)NHOR^{13}$, $-C(=O)NHN(R^{13})R^{13a}$, $-OCH_2CO_2H$, 2-(1-morpholino)ethoxy,

C1-C5 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C2-C6 alkoxyalkyl, C3-C6 cycloalkoxy, C1-C4 alkyl (alkyl being substituted with 1-5 groups selected independently from: $-NR^{13}R^{14}$, $-CF_3$, NO_2 , $-SO_2R^{13a}$, or $-S(=O)R^{13a}$),

aryl substituted with 0-2 R^{12} ,

a 5-10-membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O, said heterocyclic ring being substituted with 0-2 R^{12} ;

R^{12} is selected from one or more of the following:

phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C1-C5 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl, C7-C10 arylalkyl, C1-C5 alkoxy, $-\text{CO}_2\text{R}^{13}$, $-\text{C}(=\text{O})\text{NHOR}^{13a}$, $-\text{C}(=\text{O})\text{NHN}(\text{R}^{13})_2$, $=\text{NOR}^{13}$, $-\text{B}(\text{R}^{34})(\text{R}^{35})$, C3-C6 cycloalkoxy, $-\text{OC}(=\text{O})\text{R}^{13}$, $-\text{C}(=\text{O})\text{R}^{13}$, $-\text{OC}(=\text{O})\text{OR}^{13a}$, $-\text{OR}^{13}$, $-(\text{C1-C4 alkyl})-\text{OR}^{13}$, $-\text{N}(\text{R}^{13})_2$, $-\text{OC}(=\text{O})\text{N}(\text{R}^{13})_2$, $-\text{NR}^{13}\text{C}(=\text{O})\text{R}^{13}$, $-\text{NR}^{13}\text{C}(=\text{O})\text{OR}^{13a}$, $-\text{NR}^{13}\text{C}(=\text{O})\text{N}(\text{R}^{13})_2$, $-\text{NR}^{13}\text{SO}_2\text{N}(\text{R}^{13})_2$, $-\text{NR}^{13}\text{SO}_2\text{R}^{13a}$, $-\text{SO}_3\text{H}$, $-\text{SO}_2\text{R}^{13a}$, $-\text{S}(=\text{O})\text{R}^{13a}$, $-\text{SR}^{13}$, $-\text{SO}_2\text{N}(\text{R}^{13})_2$, C2-C6 alkoxyalkyl, methylenedioxy, ethylenedioxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4 alkylcarbonyloxy, C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, $-\text{OCH}_2\text{CO}_2\text{H}$, 2-(1-morpholino)ethoxy, C1-C4 alkyl (alkyl being substituted with $-\text{N}(\text{R}^{13})_2$, $-\text{CF}_3$, NO_2 , or $-\text{S}(=\text{O})\text{R}^{13a}$);

R^{13} is selected independently from: H, C1-C10 alkyl, C3-C10 cycloalkyl, C4-C12 alkylcycloalkyl, aryl, $-(\text{C1-C10 alkyl})\text{aryl}$, or C3-C10 alkoxyalkyl;

R^{13a} is C1-C10 alkyl, C3-C10 cycloalkyl, C4-C12 alkylcycloalkyl, aryl, $-(\text{C1-C10 alkyl})\text{aryl}$, or C3-C10 alkoxyalkyl;

when two R^{13} groups are bonded to a single N, said R^{13} groups may alternatively be taken together to form $-(\text{CH}_2)_2-5-$ or $-(\text{CH}_2)\text{O}(\text{CH}_2)-$;

R^{14} is OH, H, C1-C4 alkyl, or benzyl;

R^{21} and R^{23} are independently selected from:

hydrogen;

C1-C4 alkyl, optionally substituted with 1-6
halogen;

benzyl;

R^2 is H or C1-C8 alkyl;

R^{10} and R^{10a} are selected independently from one or
more of the following:

phenyl, benzyl, phenethyl, phenoxy, benzyloxy,
halogen, hydroxy, nitro, cyano, C1-C5 alkyl,
C3-C6 cycloalkyl, C3-C6 cycloalkylmethyl,
C7-C10 arylalkyl, C1-C5 alkoxy, $-CO_2R^{13}$, $-C(=O)N(R^{13})_2$,
 $-C(=O)NHOR^{13a}$, $-C(=O)NHN(R^{13})_2$, $=NOR^{13}$, $-B(R^{34})(R^{35})$,
C3-C6 cycloalkoxy, $-OC(=O)R^{13}$, $-C(=O)R^{13}$, $-OC(=O)OR^{13a}$,
 $-OR^{13}$, $-(C1-C4 \text{ alkyl})-OR^{13}$, $-N(R^{13})_2$, $-OC(=O)N(R^{13})_2$,
 $-NR^{13}C(=O)R^{13}$, $-NR^{13}C(=O)OR^{13a}$, $-NR^{13}C(=O)N(R^{13})_2$,
 $-NR^{13}SO_2N(R^{13})_2$, $-NR^{13}SO_2R^{13a}$, $-SO_3H$, $-SO_2R^{13a}$,
 $-S(=O)R^{13a}$, $-SR^{13}$, $-SO_2N(R^{13})_2$, C2-C6 alkoxyalkyl,
methylenedioxy, ethylenedioxy, C1-C4 haloalkyl (including
 $-C_vF_w$ where $v = 1$ to 3 and $w = 1$ to $(2v+1)$),
C1-C4 haloalkoxy, C1-C4 alkylcarbonyloxy,
C1-C4 alkylcarbonyl, C1-C4 alkylcarbonylamino, $-OCH_2CO_2H$,
2-(1-morpholino)ethoxy, C1-C4 alkyl (alkyl being
substituted with $-N(R^{13})_2$, $-CF_3$, NO_2 , or $-S(=O)R^{13a}$);

J is 3-aminopropionic acid or an L-isomer or
D-isomer amino acid of structure $-N(R^3)C(R^4)(R^5)C(=O)-$,
wherein:

R^3 is H or C1-C8 alkyl;

R^4 is H or C1-C3 alkyl;

R^5 is selected from:

hydrogen;

C1-C8 alkyl substituted with 0-2 R^{11} ;

C2-C8 alkenyl substituted with 0-2 R^{11} ;

C2-C8 alkynyl substituted with 0-2 R^{11} ;


C3-C10 cycloalkyl substituted with 0-2 R^{11} ;

aryl substituted with 0-2 R^{12} ;


a 5-10-membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, or O, said heterocyclic ring being substituted with 0-2 R^{12} ;

=O, F, Cl, Br, I, $-CF_3$, $-CN$, $-CO_2R^{13}$, $-C(=O)R^{13}$, $-C(=O)N(R^{13})_2$, $-CHO$, $-CH_2OR^{13}$, $-OC(=O)R^{13}$, $-OC(=O)OR^{13a}$, $-OR^{13}$, $-OC(=O)N(R^{13})_2$, $-NR^{13}C(=O)R^{13}$, $-NR^{14}C(=O)OR^{13a}$, $-NR^{13}C(=O)N(R^{13})_2$, $-NR^{14}SO_2N(R^{13})_2$, $-NR^{14}SO_2R^{13a}$, $-SO_3H$, $-SO_2R^{13a}$, $-SR^{13}$, $-S(=O)R^{13a}$, $-SO_2N(R^{13})_2$, $-N(R^{13})_2$, $-NHC(=NH)NHR^{13}$, $-C(=NH)NHR^{13}$, $=NOR^{13}$, NO_2 , $-C(=O)NHOR^{13}$, $-C(=O)NHN(R^{13})R^{13a}$, $=NOR^{13}$, $-B(R^{34})(R^{35})$, $-OCH_2CO_2H$, 2-(1-morpholino)ethoxy, $-SC(=NH)NHR^{13}$, N_3 , $-Si(CH_3)_3$, $(C_1-C_5 \text{ alkyl})NHR^{16}$;

$-(C_0-C_6 \text{ alkyl})X$;




, where q is independently 0,1;



- (CH₂)_mS(O)_{p'}(CH₂)₂X, where m = 1,2 and p' = 0-2;

~~wherein X is defined below; and~~

R³ and R⁴ may also be taken together to form



R³ and R⁵ can alternatively be taken together to form -(CH₂)_t- or -CH₂S(O)_{p'}C(CH₃)₂-, where t = 2-4 and p' = 0-2; or

R⁴ and R⁵ can alternatively be taken together to form -(CH₂)_u-, where u = 2-5;

R¹⁶ is selected from:

an amine protecting group;

1-2 amino acids;

1-2 amino acids substituted with an amine protecting group;


K is a D-isomer or L-isomer amino acid of structure

$-\underline{N}(R^6)CH(R^7)C(=O)-$, wherein:


R^6 is H or C1-C8 alkyl;

R^7 is selected from:


$-(C1-C7 \text{ alkyl})X$;



, wherein each q is independently 0-2 and substitution on the phenyl is at the 3 or 4 position;




, wherein each q is independently 0-2 and substitution on the cyclohexyl is at the 3 or 4 position;



$-(CH_2)_mO-(C1-C4 \text{ alkyl})-X$, where $m = 1$ or 2 ;

$-(CH_2)_mS(O)p'-(C1-C4 \text{ alkyl})-X$, where $m = 1$ or and $p' = 0-2$; and

X is selected from:




$\text{---N(R}^{13}\text{)R}^{13}$; $\text{---C(=NH)(NH}_2\text{)}$; ---SC(=NH)---NH_2 ;
 $\text{---NH---C(=NH)(NHCN)}$; $\text{---NH---C(=NCN)(NH}_2\text{)}$; $\text{---NH---C(=N-OR}^{13}\text{)(NH}_2\text{)}$;

R^6 and R^7 can alternatively be taken together to form

$$\begin{array}{c} (\text{CH}_2)_n\text{X} \\ | \\ \text{---(CH}_2\text{)}_q\text{CH(CH}_2\text{)}_q\text{---} \end{array}, \text{ wherein each } q \text{ is}$$

independently 1 or 2 and wherein $n = 0$ or 1 and X is ---NH_2




or

L is $\text{---Y(CH}_2\text{)}_v\text{C(=O)---}$, wherein:

Y is NH , N(C1-C3 alkyl) , O , or S ; and $v = 1$ or 2 ;

M is a D-isomer or L-isomer amino acid of structure



, wherein:

q' is 0-2;

R^{17} is H , C1-C3 alkyl ;

R^8 is selected from:

-CO₂R¹³, -SO₃R¹³, -SO₂NHR¹⁴, -B(R³⁴)(R³⁵), -NHSO₂CF₃,
 -CONHNHSO₂CF₃, -PO(OR¹³)₂, -PO(OR¹³)R¹³,
 -SO₂NH-heteroaryl (said heteroaryl being 5-10-membered
 and having 1-4 heteroatoms selected independently from N,
 S, or O), -SO₂NH-heteroaryl (said heteroaryl being
 5-10-membered and having 1-4 heteroatoms selected
 independently from N, S, or O), -SO₂NHCOR¹³,
 -CONHSO₂R^{13a}, -CH₂CONHSO₂R^{13a}, -NHSO₂NHCOR^{13a}, -
 NHCONHSO₂R^{13a}, -SO₂NHCONHR¹³;

R³⁴ and R³⁵ are independently selected from:

-OH,
 -F,
 -N(R¹³)₂, or
 C₁-C₈-alkoxy;

R³⁴ and R³⁵ can alternatively be taken together
 form:

a cyclic boron ester where said chain or ring
 contains from 2 to 20 carbon atoms and, optionally, 1-4
 heteroatoms independently selected from N, S, or O;

a divalent cyclic boron amide where said chain or
 ring contains from 2 to 20 carbon atoms and, optionally,
 1-4 heteroatoms independently selected from N, S, or O;

a cyclic boron amide-ester where said chain or ring
 contains from 2 to 20 carbon atoms and, optionally, 1-4
 heteroatoms independently selected from N, S, or O.